Cipla Limited is a pharmaceutical company that develops, manufactures and markets medicines in India and international markets including the United States and South Africa. Its portfolio includes generic and branded medicines, vaccines, active pharmaceutical ingredients and formulations across respiratory, cardiovascular, diabetes, oncology, urology, infectious diseases, women's health and other therapeutic areas. The company also operates in consumer healthcare, biosimilars and specialty pharmaceuticals. Cipla was incorporated in 1935 and is based in Mumbai, India.
Track the latest Cipla Limited share price along with important technical indicators in one place. This page provides a quick overview of the stock's current trend, momentum, and key price levels without switching between multiple charts.
You can check the live market price, Monthly, Weekly, Daily and Intraday trends, RSI values, Moving Averages (SMA), support & resistance levels, and the stock's 52-week high and low to better understand its overall market position.
Trend Screener automatically updates market data throughout trading hours, helping traders and investors stay informed with the latest technical analysis and trend information for 250+ NSE stocks.
This page brings together the most important technical indicators for Cipla Limited in one place. Instead of checking multiple charts, you can quickly review the stock's price action, trend, momentum, and key support and resistance levels from a single dashboard.
Whether you are an intraday trader, swing trader, or long-term investor, this page helps you quickly understand the current technical picture of Cipla before making your own investment decisions.
Disclaimer: TrendScreener.in is an educational stock analysis platform and is not a SEBI-registered Research Analyst or Investment Advisor. The information on this page is generated using technical indicators and market data and should not be considered as investment advice or buy/sell recommendations. Please do your own research before investing.